Dreyling, M. Et Al. 2018. Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. 60th Annual Meeting of the American-Society-of-Hematology (ASH) , (California, United States Of America).

Dreyling, M., Santoro, A., Mollica, L., Leppa, S., Follows, G. A., Lenz, G., ... Kim, W. S.(2018). Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma . 60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America

Dreyling, Martin Et Al. "Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma," 60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 2018

Dreyling, Martin Et Al. "Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma." 60th Annual Meeting of the American-Society-of-Hematology (ASH) , California, United States Of America, 2018

Dreyling, M. Et Al. (2018) . "Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma." 60th Annual Meeting of the American-Society-of-Hematology (ASH) , California, United States Of America.

@conferencepaper{conferencepaper, author={Martin Dreyling Et Al. }, title={Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma}, congress name={60th Annual Meeting of the American-Society-of-Hematology (ASH)}, city={California}, country={United States Of America}, year={2018}}